Rare Cell Population Analysis in Early-Stage Breast Cancer Patients
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.This study introduces a new platform for detecting rare cells in breast cancer patients, revealing abnormalities linked to systemic cancer. These findings offer new theranostic insights for early-stage disease management.
Area Of Science
- Oncology
- Cell Biology
- Medical Diagnostics
Background
- Circulating rare cells are integral to breast cancer progression and offer theranostic potential.
- Current understanding and exploration of cancer-associated rare cells are limited.
Purpose Of The Study
- To investigate and classify circulating rare cell abnormalities in early-stage breast cancer.
- To determine the association of these rare cell markers with tumor presence.
Main Methods
- Evaluation of a multi-rare-cell detection platform (Rarmax) using fluorescence and cytomorphology.
- Analysis of rare cell populations (including circulating tumor cells) before and after tumor resection in breast cancer patients and controls.
Main Results
- The Rarmax platform demonstrated linear performance and high recovery rates.
- Specific circulating epithelial and endothelial-like cell subsets were associated with cancer presence, independent of tumor status.
- High sensitivity and specificity were achieved in detecting tumor presence and cancer-associated abnormalities.
Conclusions
- Cancer-associated rare cell abnormalities can represent both tumor entities and systemic cancer.
- This approach provides a novel method for characterizing the breast cancer system and its systemic spread.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.